Algert Global LLC Has $1.42 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Algert Global LLC trimmed its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,848 shares of the company's stock after selling 33,558 shares during the period. Algert Global LLC's holdings in BridgeBio Pharma were worth $1,415,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. YHB Investment Advisors Inc. acquired a new stake in shares of BridgeBio Pharma in the 1st quarter valued at $34,000. Bfsg LLC increased its holdings in shares of BridgeBio Pharma by 175.6% during the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company's stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. Quarry LP acquired a new position in shares of BridgeBio Pharma during the 4th quarter valued at about $50,000. Headlands Technologies LLC acquired a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $48,000. Finally, EntryPoint Capital LLC bought a new stake in BridgeBio Pharma during the first quarter worth approximately $117,000. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Stock Performance

BBIO traded down $0.40 during midday trading on Friday, hitting $25.23. The company had a trading volume of 1,428,579 shares, compared to its average volume of 1,880,711. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32. The company has a market capitalization of $4.72 billion, a PE ratio of -7.96 and a beta of 1.08. The firm's 50-day simple moving average is $26.12 and its 200-day simple moving average is $26.96.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.61. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $3.96 million. The company's revenue was up 32.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.98) EPS. As a group, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -2.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson sold 4,155 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $102,586.95. Following the completion of the transaction, the chief financial officer now owns 85,192 shares of the company's stock, valued at $2,103,390.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the completion of the sale, the insider now owns 25,260,971 shares of the company's stock, valued at $650,470,003.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Brian C. Stephenson sold 4,155 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $102,586.95. Following the completion of the sale, the chief financial officer now directly owns 85,192 shares in the company, valued at $2,103,390.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,831,544 shares of company stock worth $150,128,821. Insiders own 24.66% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $43.00 price target on shares of BridgeBio Pharma in a report on Monday. Piper Sandler began coverage on BridgeBio Pharma in a report on Wednesday, September 4th. They issued an "overweight" rating and a $46.00 target price on the stock. Evercore ISI cut their price target on BridgeBio Pharma from $50.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, August 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $70.00 price objective on shares of BridgeBio Pharma in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. cut their target price on shares of BridgeBio Pharma from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, BridgeBio Pharma presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.92.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.